Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: SAGE Publications Country of Publication: United States NLM ID: 101120118 Publication Model: Print Cited Medium: Internet ISSN: 1536-0121 (Electronic) Linking ISSN: 15353508 NLM ISO Abbreviation: Mol Imaging Subsets: MEDLINE
    • بيانات النشر:
      Publication: 2024- : [Thousand Oaks, CA] : SAGE Publications
      Original Publication: Cambridge, MA : MIT Press, c2002-
    • الموضوع:
      Positron Emission Tomography Computed Tomography*; Iodine Radioisotopes/*adverse effects ; Prostate-Specific Antigen/*metabolism ; Salivary Glands/*diagnostic imaging ; Salivary Glands/*pathology; Adult ; Aged ; Humans ; Iodine Radioisotopes/pharmacokinetics ; Male ; Middle Aged
    • نبذة مختصرة :
      Introduction: Xerostomia is a well-known complication after iodine-131 ( 131 I) therapy for thyroid carcinoma. It is currently insufficiently understood how the dose and biodistribution of 131 I relates to salivary gland toxicity, and whether this is consistent for all salivary glands within a single patient. Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) was recently introduced as a new tool to evaluate the relative loss of vital acinar cells in individual salivary glands. We aimed to assess gland-specific salivary gland toxicity after 131 I-therapy using PSMA PET/CT.
      Methods: Five patients with differentiated thyroid cancer underwent [ 68 Ga]Ga-PSMA-11 PET/CT to evaluate their eligibility for peptide radioligand therapy with [ 177 Lu]Lu-PSMA-617. Uptake patterns in salivary glands were evaluated visually and quantitatively as an indicator of vital acinar cell loss after prior 131 I-therapy.
      Results: Four of 5 patients demonstrated significant lowered uptake in at least one salivary gland, after receiving at least 2 131 I-treatments. Asymmetric loss of vital acinar cells occurred by gland type (parotid/submandibular) and location (right/left). The other salivary glands in these patients and all salivary glands in the fifth patient showed normal uptake, demonstrating high intrapatient and interpatient variability.
      Conclusions: 131 I-therapy can induce salivary gland toxicity with high inter- but also high intrapatient variation among separate gland locations, which can be assessed with PSMA PET/CT. This new technique offers potential to guide further development and evaluation of protective measures in patients receiving 131 I-therapy.
    • References:
      Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):478-486. (PMID: 29523427)
      Thyroid. 2003 Mar;13(3):265-71. (PMID: 12729475)
      Thyroid. 2013 May;23(5):609-16. (PMID: 23153322)
      Clin Nucl Med. 2018 Aug;43(8):e265-e268. (PMID: 29894335)
      J Clin Endocrinol Metab. 2003 Apr;88(4):1880-8. (PMID: 12679487)
      Pharmaceutics. 2019 Oct 29;11(11):. (PMID: 31671763)
      Clin Nucl Med. 2002 Nov;27(11):767-71. (PMID: 12394122)
      Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1310-9. (PMID: 17482767)
      J Nucl Med. 2016 Nov;57(11):1685-1691. (PMID: 27339871)
      J Dent Res. 2009 Oct;88(10):894-903. (PMID: 19783796)
      Thyroid. 2013 Aug;23(8):1029-36. (PMID: 23441638)
      J Nucl Med. 2017 Oct;58(10):1545-1552. (PMID: 28687599)
      Nucl Med Commun. 2006 Jun;27(6):495-9. (PMID: 16710103)
      Rheumatology (Oxford). 2016 Feb;55(2):237-45. (PMID: 26338664)
      EJNMMI Res. 2018 Jul 3;8(1):56. (PMID: 29971556)
      Sci Transl Med. 2015 Sep 16;7(305):305ra147. (PMID: 26378247)
      Cancer Treat Rev. 2015 Dec;41(10):925-34. (PMID: 26421813)
      Clin Nucl Med. 2008 Sep;33(9):638-40. (PMID: 18716518)
      Cancer. 2006 Dec 1;107(11):2525-34. (PMID: 17078052)
      Med Phys. 2011 Oct;38(10):5412-9. (PMID: 21992360)
      Eur J Nucl Med Mol Imaging. 2010 Dec;37(12):2298-306. (PMID: 20625723)
      Support Care Cancer. 2016 Jun;24(6):2735-41. (PMID: 26805558)
      Nucl Med Commun. 2014 Feb;35(2):210-6. (PMID: 24177041)
      J Radiol Case Rep. 2015 Jun 30;9(6):44-9. (PMID: 26622936)
      J Am Dent Assoc. 2007 Dec;138(12):1582-7. (PMID: 18056102)
    • Contributed Indexing:
      Keywords: 131I; PSMA PET/CT; case series; radionuclide therapy; salivary glands; thyroid carcinoma; toxicity
    • الرقم المعرف:
      0 (Iodine Radioisotopes)
      0 (Iodine-131)
      EC 3.4.21.77 (Prostate-Specific Antigen)
    • الموضوع:
      Date Created: 20200704 Date Completed: 20210701 Latest Revision: 20210701
    • الموضوع:
      20250114
    • الرقم المعرف:
      PMC7493237
    • الرقم المعرف:
      10.1177/1536012120934992
    • الرقم المعرف:
      32619138